UK – NICE u-turn backs Roche’s Tecentriq for triple negative breast cancer

NICE is now backing NHS use of Tecentriq (atezolizumab) with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer, following an “improved offer” from drugmaker Roche.

In draft guidelines, the Institute said its earlier rejection has been overturned after the company updated its economic model and agreed to provide a larger discount to the list price of the drug following a deal with NHS England and NHS Improvement.

Tecentriq, given with chemotherapy drug nab-paclitaxel, is the first immunotherapy that specifically targets triple negative breast cancer where tumours have PD-L1 expression of 1% or more.

It is given by injection every two weeks to people who have not had chemotherapy for breast cancer that has spread to other parts of the body and where surgery to remove it is not possible…